Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- IDXG +48.6%, NLST +18.3%, KGJI +18.3%, LNN +12.8%, BCLI +6.5%
- RXII +5.8%, NAVB +4.8%, AFMD +2.1%, VRML +1.4%
M&A news:
- COP +7.5% (Cenovus Energy acquires ConocoPhillips' 50% interest in the FCCL Partnership; COP will add $3 bln to repurchase authorization; also upgraded to Buy from Neutral at UBS)
Other news:
- BVXV +44.1% (receives grant from Israel's Ministry of Economy and Industry to build facility for production of universal flu vaccine candidate M-001)
- EXTR +20% (Broadcom enters agreement to sell its data center center switching, routing, and analytics business to Extreme Networks for $55 mln in cash; transaction contingent on Broadcom closing its proposed acquisition of Brocade)
- ANTH +14% (announces the findings from the Extension Period of the Phase 3 SOLUTION; demonstrates comparable maintenance in key measurements of height, weight, and BMI)
- OMER +8.4% (data from its Phase 2 clinical trial of OMS721)
- HTGM +7.6% (rebounding from recent offering related pullback; also higher despite GlaxoSmithKline lowering active stake / disclosing the sale of 300k shares)
- AVXL +5.5% (announces that the dismissal of the appeal in the Cortina v. Anavex Life Sciences Corp lawsuit)
- HSKA +5.2% (light volume; will replace Wintrust Financial in the SmallCap 600)
- INCR +4.9% (will replace CEB Inc. in the S&P MidCap 400),
- GMO +4.3% (continued strength)
- MICT +3.2% (receives 3 purchase orders in the last two weeks from a large private Aerospace & Defense contractor)
- NVTA +1.7% (announces an expansion of its genetic testing services)
Analyst comments:
- ESPR +5.3% (upgraded to Buy from Neutral at UBS)
- FDX +0.8% (upgraded to Positive from Neutral at Susquehanna)